AXR Amrep

AMREP Reports Second Quarter Fiscal 2025 Results

AMREP Reports Second Quarter Fiscal 2025 Results

HAVERTOWN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,042,000, or $0.75 per diluted share, for its 2025 fiscal second quarter ended October 31, 2024 compared to net income of $1,108,000, or $0.21 per diluted share, for the same period of the prior year. For the first six months of 2025, AMREP had net income of $8,106,000, or $1.51 per diluted share, compared to net income of $2,454,000, or $0.46 per diluted share, for the same period of 2024. Revenues were $11,906,000 and $30,997,000 for the second quarter and first six months of 2025 and $8,854,000 and $19,143,000 for the second quarter and first six months of 2024.

More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which have today been filed with the Securities and Exchange Commission and will be available on AMREP’s website (/sec-filings/). As a result of many factors, including the nature and timing of specific transactions and the type and location of land or homes being sold, revenues, average selling prices and related gross margins from land sales or home sales can vary significantly from period to period and prior results are not necessarily a good indication of what may occur in future periods.

AMREP Corporation, through its subsidiaries, is a major holder of land, leading developer of real estate and award-winning homebuilder in New Mexico.

 
FINANCIAL HIGHLIGHTS
 
  Three Months Ended October 31,
  2024 2023
Revenues $11,906,000 $8,854,000
       
Net income $4,042,000 $1,108,000
Earnings per share – basic $0.76 $0.21
Earnings per share – diluted $0.75 $0.21
       
Weighted average number of common shares outstanding – basic  5,320,000  5,301,000
Weighted average number of common shares outstanding – diluted  5,374,000  5,339,000
 
  Six Months Ended October 31,
  2024 2023
Revenues $30,997,000 $19,143,000
       
Net income $8,106,000 $2,454,000
Earnings per share – basic $1.53 $0.46
Earnings per share – diluted $1.51 $0.46
       
Weighted average number of common shares outstanding – basic  5,314,000  5,296,000
Weighted average number of common shares outstanding – diluted  5,367,000  5,333,000



  
CONTACT:Adrienne M. Uleau
 Vice President, Finance and Accounting
 (610) 487-0907


EN
13/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amrep

Amrep Corp: 1 director

A director at Amrep Corp sold 13,000 shares at 31.558USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

AMREP Reports Second Quarter Fiscal 2025 Results

AMREP Reports Second Quarter Fiscal 2025 Results HAVERTOWN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,042,000, or $0.75 per diluted share, for its 2025 fiscal second quarter ended October 31, 2024 compared to net income of $1,108,000, or $0.21 per diluted share, for the same period of the prior year. For the first six months of 2025, AMREP had net income of $8,106,000, or $1.51 per diluted share, compared to net income of $2,454,000, or $0.46 per diluted share, for the same period of 2024. Revenues were $11,906,000 and $30,997,000 ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 19, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 12, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

LUV SOUTHWEST AIRLINES CO
TTSH TILE SHOP HOLDINGS INC.
MOFG MIDWESTONE FINANCIAL GROUP
MEI METHODE ELECTRONICS INC.
KVHI KVH INDUSTRIES INC.
GDOT GREEN DOT CORPORATION CLASS A
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
CODI COMPASS DIVERSIFIED HOLDINGS
CDXS CODEXIS
AHH ARMADA HOFFLER PROPERTIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
A0JMXQ INDIA CAPITAL GROWTH FUND LTD.
RLMD RELMADA THERAPEUTICS
CULP CULP INC.
EBF ENNIS
APTV APTIV PLC
NANX NANOPHASE TECHNOLOGIES CORP.
AXR AMREP
ETON ETON PHARMACEUTICALS
STIM STIMSONITE CORP
INMB INMUNE BIO
NFE INC.
CAPR NEW FORTRESS ENERGY
EPSN CAPRICOR THERAPEUTICS
FBIO EPSILON ENERGY LIMITED
WSC FABIEN CORP
VRDN WILLSCOT MOBILE MINI HOLDINGS CORP
CTLP VIRIDIAN THERAPEUTICS INC
SMMT CANTALOUPE
PFBX INC.
BMEA SUMMIT THERAPEUTICS INC
FTHY PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ASLE BIOMEA FUSION
BHVN INC.
BIGZ FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
BUKS AERSALE CORP
ECBK BIOHAVEN LTD
CDIO BLACKROCK INNOVATION AND GROWTH TST
GRNT BUTLER NATIONAL CORP
GTE ECB BANCORP INC.
CRBP CARDIO DIAGNOSTICS HLDGS INC
BMEZ GRANITE RIDGE RESOURCES INC
ASGI GRAN TIERRA ENERGY INC.
SYRS CORBUS PHARMACEUTICALS HOLDINGS INC.
PEO BLACKROCK HEALTH SCIENCES TERM TRUST
XPER ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
OMIC SYROS PHARMACEUTICALS INC.
PMN PETROLEUM & RESOURCES CORPORATION
BNTC XPERI INC
CLNN SINGULAR GENOMICS SYSTEMS INC
BNZI PROMIS NEUROSCIENCES INC.
SIRI BENITEC BIOPHARMA INC
CLENE INC
BANZAI INTERNATIONAL INC
SIRIUS XM HLDGS INC NEW
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 5, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch